190 likes | 280 Views
Hepatitis С as risk marker of HIV infection development in the epidemiological surveillance system of HIV infection in Kazakhstan. Central Asia Program (CDC), Centers for Disease Control and Prevention, USA Republican Center for Prevention and Combating AIDS, Каzаkhstan
E N D
Hepatitis С as risk marker of HIV infection development in the epidemiological surveillance system of HIV infection in Kazakhstan Central Asia Program (CDC), Centers for Disease Control and Prevention, USA Republican Center for Prevention and Combating AIDS, Каzаkhstan N.G.Kovtunenko, V.V.Zeman, E.K.Lyudvikova
Epidemiological situation on the HIV/AIDS in Republic Kazakhstan on 01.08.2004 (all results taken from RC AIDS) • In RK officially registered 4418 HIV-infected, from them 192 people living with AIDS • 77,5% (3424) infected are men and 24,5%(994) infected are women • The most affected age group is people from the age of 20 to 29 (2389)
Relative density of HIV- infection cases based on the ways of transmission (01.06.2004)
Objectives:To study the prevalence of HVC in the area with high density of HIV infection from the injecting drug users (IDU)
Tasks: - To find demographical characteristics in HIV and HVC prevalence in IDU groups -To determine a correlation between the spreading of HVC and HIV in IDU group -To define a connection between the HVC prevalence in IDU groups and duration of the drug abuse
MATERIALS AND METHODS • A cross sectional sampling study was conducted in Karaganda region were 1796 IDU participated, May-August 2002. • Participation in the study was anonymous and voluntary, based on the informational agreement. • according to standard RC AIDS questionnaire IDU have been questioned about the injection practice, sexual behavior and etc,. • Received blood samples from the IDU were tested for HIV and HVC. • Participants were consulted before and after testing.
MATERIALS AND METHODS • Based on the questionnaire facts, a database was created which included the following information: Demographical facts, history of drug abuse, medical injections, use of syringe, sexual behavior (including condoms use) and hepatitis case history. • In addition, the data base included results of laboratory analysis: primary screening ELISA, confirming ELISA, data immunoblot (IB) with specific antigens. • Results of analysis could be known from the individual code • All results of the research were checked in Atlanta, Georgia (USA) and received 100% confirmation.
DETERMINATION OF CASE • Individuals were considered as anti-HIV positive, when primary screening (ELISA) showed positive result of anti-HIV and was confirmed by secondary screening ELISA and extra test of IB (Western Blot). • Individuals considered as anti-HVC positive, when primary screening ELISA discovered positive result of anti-HVC and confirmed by secondary expert test of ELISA.
Prevalence of HIV and HVC serological markers in the IDU groups
Prevalence of HIV and HVC in IDU groups base on the epidemiological surveillance (main base) 2003г.
Prevalence of HIV and HVC in IDU groups base on the epidemiological surveillance (main base) 2004г.
CONCLUSION • Prevalence of HVC in IDU group varies in deferent regions and reaches 80%. • The prevalence of HVC increases depending on the duration of drug abuse and does not change while drug abuse exceeds 5 years. • Spreading of HVC in men is more than in women in the studied groups. • Infection with hepatitis C compared to HIV occurs earlier in IDU group.
CONCLUSION • Presence of hepatitis C can serve as an indirect marker for finding a high risk group by HIV infecting. • When detecting the center of the high prevalence of HVC, HIV infection can be expected in this group and perform proper actions to prevent and control this infection.